FDA Brief

Warning letters Drugs

FDA warning letter to

Natuzen Co., Ltd.

High riskIssued May 3, 2024Posted May 14, 2024Center for Drug Evaluation and Research | CDER

Natuzen Co., Ltd. failed drug manufacturing rules for OTC products including Atoren Hand Sanitizer, with no methanol testing, cleaning validation, or quality unit.

What happened

FDA reviewed records Natuzen submitted in response to FDA requests dated March 29, May 9, and July 8, 2022, and October 6, 2023, under section 704(a)(4) of the FD&C Act. The records showed no test of ethanol for methanol, inadequate cleaning procedures and validation for non-dedicated equipment, and a statement that Natuzen had no quality unit. FDA also placed Natuzen on Import Alert 66-40 on April 29, 2024.

What FDA found

  1. Natuzen did not test its active ingredient ethanol for methanol.

    21 CFR 211.84(d)(1)
  2. Natuzen lacked adequate written cleaning and maintenance procedures for non-dedicated equipment, and could not validate cleaning without them.

    21 CFR 211.67(b)
  3. Natuzen stated it had no quality unit to approve or reject materials and products.

    21 CFR 211.22(a)

What FDA wants

FDA tells Natuzen to correct violations promptly and respond in writing within 15 working days with corrective actions and prevention, or give reasons for delay and a completion schedule. FDA also recommends engaging a qualified current good manufacturing practice (CGMP) consultant to perform a six-system audit before resuming drug manufacturing for the U.S. market.

Who should pay attention

  • brands that buy OTC drugs or hand sanitizer from this contract manufacturer
  • U.S. importers and distributors of Natuzen drug products
  • suppliers of ethanol or raw materials to hand sanitizer makers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Sklar Personal Care Inc.

    Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.

    High risk
  2. Naturich Cosmetique Labs

    FDA warned Naturich Cosmetique Labs over inadequate manufacturing controls for over-the-counter topical drugs, including contaminated water and untested ingredients.

    High risk
  3. Nature’s Fusions LLC

    FDA cited Nature's Fusions for over-the-counter hand sanitizer manufacturing with inadequate stability, component and finished-product testing, and water controls.

    High risk
  4. Medical Chemical Corporation

    FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.

    High risk